SVB Wealth’s KalVista Pharmaceuticals KALV Stock Holding History

SVB Wealth’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,801	Closed	-$200K	–	1008
2021 Q1	$200K	Buy	+7,801	New	+$205K	﹤0.01%	835

Other funds holding KALV

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SVB Wealth's KALV Position: Q2 2021 in Review

SVB Wealth sold out of KalVista Pharmaceuticals (KALV) in Q2 2021, closing a stake of 7,801 shares — an estimated $200K sold.

SVB Wealth first reported a position in KALV in Q1 2021 and held it in 1 quarter. The position peaked at $200K in Q1 2021. 110 funds tracked by Wall St. Rank hold KALV as of Q2 2021.

SVB Wealth reported no remaining KalVista Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
SVB Wealth sold 7,801 KalVista Pharmaceuticals shares in Q2 2021, an estimated $200K.
SVB Wealth first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 1 quarter.
SVB Wealth's KalVista Pharmaceuticals position peaked at $200K in Q1 2021.
110 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2021.

Based on SVB Wealth's 13F filing for Q2 2021, filed 13 Aug 2021.